Synact Pharma Aps

This study is testing an investigational drug called AP1189 to see if it can help control a rare kidney disease. It will involve about 23 adults who have this disease and are already on standard blood pressure medications. The main goal is to see if adding AP1189 for 12 weeks is …

This study is testing if a new oral drug called AP1189, when added to the standard medication methotrexate, can better control disease activity in people recently diagnosed with rheumatoid arthritis. It will involve 240 participants who have not yet tried other powerful arthritis…